Indrayuni, Ni Made Dwi and Tri E., Erfan and Irfan, Baharudin and Hati, Sari Kusuma and Abdullah, Siti Saharah (2021) A Review On: Novel Drug Delivery Technology Of Rituximab. World Journal of Pharmaceutical Research, 10 (2). ISSN 2277– 7105
Preview |
PDF
WJPR 19764.pdf Download (409kB) | Preview |
Abstract
Rituximab can be used for the treatment of severe rheumatoid arthritis, follicular lymphoma phase III-IV, follicular non-hodgkins lymphoma, chronic lymphocytic leukimia therapy, advance therapy of granulomatosis polyangiitis and microscopic polyitis. Rituximab is a two compartment with an average half-life of 87 ± 18 hours and a volume distribution of 1.3L. Administration of rituximab at a dose of 375 mg / m2 in 4 consecutive weeks can increase serum drug concentration in each administration by infusion. This review article focuses on biosimilar technology of rituximab was carried out by increasing the teraupetic mechanism and the response to the potential effects of binding B-mAB in NHL disease. The development of biosimilar rituximab approved by the FDA, namely ofatumab (anti CD20) and Obinutuzumab (mAb from rituximab with a different glucose group).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Rituximab, Biosimilar, NHL disease |
| Subjects: | R Medicine > RS Pharmacy and materia medica |
| Divisions: | Postgraduate Programs > Master Program in Clinical Pharmacy |
| Depositing User: | Ester Sri W. 196039 |
| Date Deposited: | 09 Mar 2021 07:50 |
| Last Modified: | 31 Mar 2021 02:39 |
| URI: | http://repository.ubaya.ac.id/id/eprint/39006 |
Actions (login required)
 |
View Item |
